Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults

Document first published:: 17 July 2019
Page updated:: 18 July 2019
Topic:
Publication type:: Policy, Report

NHS England will commission bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults in accordance with the criteria outlined in this policy.

Document

Clinical Commissioning Policy: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Commissioning Policy: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
160 KB

Document

Clinical Panel Report 1: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Panel Report 1: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
95 KB

Document

Clinical Panel Report 2: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Clinical Panel Report 2: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
96 KB

Document

Consultation Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Consultation Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
64 KB

Document

CPAG Summary Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

CPAG Summary Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
61 KB

Document

Engagement Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Engagement Report: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
51 KB

Document

Evidence Review: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

Evidence Review: Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV

PDF
586 KB